New drug cuts bad cholesterol by nearly 60% in first-year trials
Enlicitide, a new daily pill, showed impressive results in people with inherited high cholesterol (HeFH). In a year-long trial, it cut LDL or "bad" cholesterol by about 55-58% and reduced other harmful blood fats. It was well tolerated, with side effects similar to a placebo. Further studies will examine its impact on heart attack and stroke risk.